Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Kalytera Defaults on GVHD Program

<< Previous

Bullboard Posts

Next >>

Comment by MiSdyngNASTYon May 25, 2020 12:29pm

68 Views

Post# 31069229

RE:Kalytera Defaults on GVHD Program

How is this a successful company?

MiSdyngNASTY wrote: No revenue. Can't pay debts up to 100m now. Defaulting on GVHD program. Will lose it back to Talent. Begging for a new "acquisition". You all got played again. Same old scam shell company Kalytera. Kalytera acquired its GVHD program through the acquisition of Talent Biotechs Ltd. (Talent) in 2017. Kalyteras subsidiary, Kalytera Therapeutics Israel Ltd. (Kalytera Israel) owns the assets of the GVHD program, and is in default under a Promissory Note evidencing a USD $3 million debt that is owed by Kalytera Israel to the former shareholders of Talent

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it